EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation

Maria Nuria Peralta-Moreno iD, Yago Mena, David Ortega-Alarcon iD, Ana Jimenez-Alesanco iD, Sonia Vega, Olga Abian iD, Adrian Velazquez-Campoy iD, Timothy M Thomson iD, Marta Pinto, José M Granadino-Roldán iD, Maria Santos Tomas, Juan J Perez iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25116119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Maria Nuria Peralta-Moreno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Materials Science and Physical Chemistry, Institut de Recerca en Quimica Teòrica i Computacional (IQTCUB), University of Barcelona (UB)…. Hauptthemen laut MEDLINE: Molecular Docking Simulation, SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya, Spanish Structures and Excellence María de Maeztu program, Universitat de Barcelona PREDOCS-UB 2020 grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of specific antiviral therapies targeting SARS-CoV-2 remains fundamental because of the continued high incidence of COVID-19 and limited accessibility to antivirals in some countries. In this context, dark chemical matter (DCM), a set of drug-like compounds with outstanding selectivity profiles that have never shown bioactivity despite being extensively assayed, appears to be an excellent starting point for drug development. Accordingly, in this study, we performed a high-throughput screening to identify inhibitors of the SARS-CoV-2 main protease (Mpro) using DCM compounds as ligands. Multiple receptors and two different docking scoring functions were employed to identify the best molecular docking poses. The selected structures were subjected to extensive conventional and Gaussian accelerated molecular dynamics. From the results, four compounds with the best molecular behavior and binding energy were selected for experimental testing, one of which presented inhibitory activity with a Ki value of 48 ± 5 μM. Through virtual screening, we identified a significant starting point for drug development, shedding new light on DCM compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationSARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsMolecular Dynamics SimulationProtease InhibitorsHumansCOVID-19Drug DiscoveryHigh-Throughput Screening AssaysDrug Evaluation, PreclinicalProtein BindingLigands

Stichwörter der Autor:innen

MMPB/GBSA approachSARS-CoV-2 main proteasedark chemical matterdockingdrug designmolecular dynamicsvirtual screening

Substanzen

Coronavirus 3C ProteasesAntiviral AgentsProtease InhibitorsLigands

Autor:innen und Institutionen

  • Department of Materials Science and Physical Chemistry, Institut de Recerca en Quimica Teòrica i Computacional (IQTCUB), University of Barcelona (UB), 08028 Barcelona, Spain.
  • Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.
  • Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, 50009 Zaragoza, Spain.
  • Instituto de Investigación Sanitaria de Aragón (IIS Aragon), 50009 Zaragoza, Spain.
  • Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas Digestivas (CIBERehd), 28029 Madrid, Spain.
  • Institute of Molecular Biology of Barcelona (IBMB-CSIC), 08028 Barcelona, Spain.

ORCID-Profile: Maria Nuria Peralta-Moreno, David Ortega-Alarcon, Ana Jimenez-Alesanco, Olga Abian, Adrian Velazquez-Campoy, Timothy M Thomson, José M Granadino-Roldán, Juan J Perez, Jaime Rubio-Martinez

Förderung

  • The Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya
  • Spanish Structures and Excellence María de Maeztu program
  • Universitat de Barcelona PREDOCS-UB 2020 grant
  • Fundación hna
  • Fondo Investiga COVID-19 from Instituto de Investigación Sanitaria de Aragón IIS-A
  • Spanish Ministry of Economy and Competitiveness
  • FPI predoctoral contract
  • Ministry of Science and Innovation

Zitieren

APA

Peralta-Moreno, M. N., Mena, Y., Ortega-Alarcon, D., Jimenez-Alesanco, A., Vega, S., Abian, O., Velazquez-Campoy, A., Thomson, T. M., Pinto, M., Granadino-Roldán, J. M., Santos Tomas, M., Perez, J. J., & Rubio-Martinez, J. (2024). Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116119

Vancouver

Peralta-Moreno MN, Mena Y, Ortega-Alarcon D, Jimenez-Alesanco A, Vega S, Abian O, et al. Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116119

BibTeX
@article{PeraltaMoreno2024,
  author = {Peralta-Moreno, Maria Nuria and Mena, Yago and Ortega-Alarcon, David and Jimenez-Alesanco, Ana and Vega, Sonia and Abian, Olga and Velazquez-Campoy, Adrian and Thomson, Timothy M and Pinto, Marta and Granadino-Roldán, José M and Santos Tomas, Maria and Perez, Juan J and Rubio-Martinez, Jaime},
  title = {Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25116119}
}
Kostenlos starten →